drugset / Trial / NCT04421508

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508

Phase 3 Terminated 191 enrolled Bellerophon Pulse Technologies
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.

Timeline

Start
2020-07-12
Primary completion
2020-12-28
Completion
2021-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 125 ug/kg Inhaled

Indications